These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22054413)

  • 1. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
    Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
    Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
    Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
    Sawada T; Fuchinoue S; Teraoka S
    Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of ABO-incompatible grafts in living donor liver transplantation--first report from India.
    Soin AS; Raut V; Mohanka R; Rastogi A; Goja S; Balachandran M; Saigal S; Saraf N; Bhangui P; Sumana KR; Singla P; Srinivasan T; Choudhary N; Tiwari A; Raina V; Govil D; Mohan N; Vohra V
    Indian J Gastroenterol; 2014 Jan; 33(1):72-6. PubMed ID: 24369388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO-incompatible kidney transplantation in elderly patients over 60 years of age.
    Uchida J; Iwai T; Machida Y; Kuwabara N; Kabei K; Murao M; Otoshi T; Naganuma T; Kumada N; Nakatani T
    Int Urol Nephrol; 2012 Oct; 44(5):1563-70. PubMed ID: 22828739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience.
    Shirakawa H; Ishida H; Shimizu T; Omoto K; Iida S; Toki D; Tanabe K
    Clin Transplant; 2011; 25(6):878-84. PubMed ID: 21175849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K; Hyodo Y; Aikawa A
    Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab.
    Raut V; Mori A; Kaido T; Ogura Y; Taku I; Nagai K; Sasaki N; Endo K; Hata T; Yagi S; Egawa H; Uemoto S
    Transplantation; 2012 Jan; 93(1):99-105. PubMed ID: 22094955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
    Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.
    Sonnenday CJ; Warren DS; Cooper M; Samaniego M; Haas M; King KE; Shirey RS; Simpkins CE; Montgomery RA
    Am J Transplant; 2004 Aug; 4(8):1315-22. PubMed ID: 15268734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.